• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Friday, October 24, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News

Engineering cells to make immunotherapy more effective

Bioengineer by Bioengineer
May 1, 2017
in Science News
Reading Time: 3 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram
IMAGE

Credit: University of Houston

Immunotherapy, in which cells from the human immune system are unleashed to fight disease, has been the big story in cancer treatment over the past few years. When it works, it can spur long-lasting remission in patients for whom other treatments have failed. But most patients don't benefit, and there is still no good way to predict who will respond.

A team of researchers led by an engineer from the University of Houston is trying another tack – designing immune system cells that can survive within a tumor even when the nutrients needed to sustain them aren't available. That should allow the cells to work more efficiently in more people.

Navin Varadarajan, associate professor of chemical and biomolecular engineering at UH, works with T cells, immune cells that can recognize and attack disease cells. But all cells need nutrients to survive, and tumors harbor areas of nutrient limited zones, meaning T cells often die before completing their task, Varadarajan said.

"We know once they get to the tumor, nutrients are limited," he said. "If they are not able to cope and compete effectively for these nutrients, they're going to die. The question is, can you engineer the T cells to survive and persist?"

To further the work, Varadarajan has received a $375,000, three-year grant from the Melanoma Research Alliance, part of $8.5 million in new funding awarded to researchers at 28 institutions in six countries.

"These awards will further our ability to improve melanoma outcomes, support the next generation of melanoma researchers and help draw us ever closer to a cure," said Debra Black, chair and co-founder of the Melanoma Research Alliance.

Varadarajan's work will use a novel research platform he developed to allow researchers to study T cells at a single-cell level, as well as single cell T cell-tumor cell interactions. The proprietary chip-based platform works by co-incubating T cells and tumor cells in dense arrays of nanoliter wells, or nanowells, and monitoring the functional interaction between the cells. The goal is to engineer T cells that retain their anti-cancer properties in the inhospitable environment of a tumor.

The platform will allow researchers to track thousands of interactions and hone in on the traits that predict success. The engineered T cells will then be tested in mice at the University of Texas MD Anderson Cancer Center. This work builds on existing research conducted by Melisa Martinez, a postdoctoral researcher in Varadarajan's lab, in collaboration with an MD Anderson team headed by Chantale Bernatchez.

Varadarajan began working on immunotherapy after arriving at UH about seven years ago. Since then, the therapy has taken off.

"It's amazing how well it's done," he said. "It's become a major player in clinical oncology. All of our work now is going toward getting it to work for more people."

He said the treatment is effective for about 20 percent of patients who receive it.

"For now, we don't have good biomarkers to tell who is a good candidate for immunotherapy," he said. Engineering T cells to work more broadly could be another way to increase the therapy's effectiveness. "It's a complementary approach."

###

Media Contact

Jeannie Kever
[email protected]
713-743-0778
@UH_News

http://www.uh.edu/news-events

############

Story Source: Materials provided by Scienmag

Share12Tweet7Share2ShareShareShare1

Related Posts

Chemoenzymatic Creation of Medium- and Long-Chain TAGs

Chemoenzymatic Creation of Medium- and Long-Chain TAGs

October 24, 2025
Indigenous Bacteria Boost Plant Growth, Combat Nematodes

Indigenous Bacteria Boost Plant Growth, Combat Nematodes

October 24, 2025

iPSCs with APTX Mutations Show Defective Differentiation

October 24, 2025

Nursing Students’ Attitudes Toward Transgender Individuals in Türkiye

October 24, 2025
Please login to join discussion

POPULAR NEWS

  • Sperm MicroRNAs: Crucial Mediators of Paternal Exercise Capacity Transmission

    1280 shares
    Share 511 Tweet 320
  • Stinkbug Leg Organ Hosts Symbiotic Fungi That Protect Eggs from Parasitic Wasps

    309 shares
    Share 124 Tweet 77
  • ESMO 2025: mRNA COVID Vaccines Enhance Efficacy of Cancer Immunotherapy

    187 shares
    Share 75 Tweet 47
  • New Study Suggests ALS and MS May Stem from Common Environmental Factor

    133 shares
    Share 53 Tweet 33

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Chemoenzymatic Creation of Medium- and Long-Chain TAGs

Indigenous Bacteria Boost Plant Growth, Combat Nematodes

iPSCs with APTX Mutations Show Defective Differentiation

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 66 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.